Home » Stocks » SCYX

SCYNEXIS, Inc. (SCYX)

Stock Price: $8.08 USD -0.60 (-6.91%)
Updated Mar 4, 2021 2:05 PM EST - Market open
Market Cap 171.79M
Revenue (ttm) n/a
Net Income (ttm) -26.93M
Shares Out 10.63M
EPS (ttm) -3.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $8.08
Previous Close $8.68
Change ($) -0.60
Change (%) -6.91%
Day's Open 8.86
Day's Range 7.89 - 8.87
Day's Volume 550,364
52-Week Range 4.20 - 10.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

JERSEY CITY, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug...

GlobeNewsWire - 6 days ago

JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-...

GlobeNewsWire - 1 week ago

JERSEY CITY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-...

GlobeNewsWire - 2 weeks ago

JERSEY CITY, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-...

Business Wire - 2 weeks ago

JERSEY CITY, N.J. & SHANGHAI--(BUSINESS WIRE)--SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resist...

GlobeNewsWire - 2 months ago

JERSEY CITY, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-fun...

GlobeNewsWire - 2 months ago

JERSEY CITY, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warra...

GlobeNewsWire - 2 months ago

JERSEY CITY, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warran...

GlobeNewsWire - 2 months ago

JERSEY CITY, N.J., Dec. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-...

GlobeNewsWire - 2 months ago

JERSEY CITY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-...

Insider Monkey - 3 months ago

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel ...

GlobeNewsWire - 3 months ago

JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-...

GlobeNewsWire - 3 months ago

JERSEY CITY, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to potentially overcome and prevent difficult-to-tre...

GlobeNewsWire - 4 months ago

Three posters highlight the potential for ibrexafungerp use in treating and preventing serious fungal infections Three posters highlight the potential for ibrexafungerp use in treating and pre...

GlobeNewsWire - 4 months ago

JERSEY CITY, N.J., Oct. 14, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-...

GlobeNewsWire - 4 months ago

Presentations to showcase in vitro activity of ibrexafungerp against fluconazole-susceptible and -resistant Candida spp. and clinical data from VANISH-303 PHASE 3 trial evaluating ibrexafunger...

GlobeNewsWire - 5 months ago

JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dr...

GlobeNewsWire - 6 months ago

JERSEY CITY, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and d...

GlobeNewsWire - 6 months ago

In July, SCYNEXIS announced that it had successfully conducted pre-NDA meetings with the FDA regarding ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC) more commonly known as ...

GlobeNewsWire - 7 months ago

JERSEY CITY, N.J., July 29, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and d...

GlobeNewsWire - 7 months ago

Clinical and preclinical studies demonstrate ibrexafungerp’s broad-spectrum activity and potential to treat a range of serious and life-threatening fungal infections Clinical and preclinical s...

GlobeNewsWire - 7 months ago

Discussion will be conducted via Webcast Call on Tuesday, July 14th at 10am Eastern Time

GlobeNewsWire - 8 months ago

JERSEY CITY, N.J., June 08, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dru...

GlobeNewsWire - 9 months ago

JERSEY CITY, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dru...

GlobeNewsWire - 9 months ago

JERSEY CITY, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug...

GlobeNewsWire - 9 months ago

JERSEY CITY, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug...

GlobeNewsWire - 10 months ago

JERSEY CITY, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and ...

GlobeNewsWire - 10 months ago

SCYNEXIS has the ability, at its discretion, to efficiently access up to $20 million of capital

GlobeNewsWire - 10 months ago

JERSEY CITY, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dr...

Seeking Alpha - 1 year ago

Scynexis: A Promising Infectious Diseases Player For 2020

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in SCYNEXIS.

Zacks Investment Research - 1 year ago

Scynexis (SCYX) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to SCYNEXIS (SCYX) stock based on the movements in the options market lately.

Zacks Investment Research - 1 year ago

Scynexis (SCYX) delivered earnings and revenue surprises of 11.11% and -5.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

I expect LPAD designation to be granted to both FURI and CARES trials before the end of this year.

Seeking Alpha - 1 year ago

Shares have risen by 25% since my January update piece.

Seeking Alpha - 1 year ago

Scynexis is a development stage biotechnology developing a novel antifungal, Ibrexafungerp, with a high probability of success.

Zacks Investment Research - 1 year ago

Scynexis (SCYX) delivered earnings and revenue surprises of -20.00% and -24.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Scynexis (SCYX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About SCYX

SCYNEXIS, a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
May 2, 2014
CEO
Dr. Marco Taglietti
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
SCYX
Full Company Profile

Financial Performance

In 2019, SCYNEXIS's revenue was $121,000, a decrease of -52.92% compared to the previous year's $257,000. Losses were -$53.71 million, 330.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for SCYNEXIS stock is "Strong Buy." The 12-month stock price forecast is 30.57, which is an increase of 278.34% from the latest price.

Price Target
$30.57
(278.34% upside)
Analyst Consensus: Strong Buy